BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32045874)

  • 1. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
    Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
    Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of perampanel treatment on quality of life and psychiatric symptoms in patients with drug-resistant focal epilepsy: An observational study in Italy.
    Deleo F; Quintas R; Turner K; Didato G; Zambrelli E; Pappalardo I; Chiesa V; Pastori C; de Curtis M; Canevini MP; Villani F
    Epilepsy Behav; 2019 Oct; 99():106391. PubMed ID: 31371205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
    Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
    Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment.
    Huber B; Schmid G
    Epilepsy Behav; 2017 Jan; 66():74-79. PubMed ID: 28038390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
    Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
    Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours.
    Maurousset A; Limousin N; Praline J; Biberon J; Corcia P; De Toffol B
    Epilepsy Behav; 2016 Aug; 61():237-241. PubMed ID: 27393930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
    Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
    Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
    Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
    Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy.
    Lancman ME; Fertig EJ; Trobliger RW; Perrine K; Myers L; Iyengar SS; Malik M
    Epilepsy Behav; 2016 Aug; 61():27-33. PubMed ID: 27315132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy.
    Brodie MJ; Stephen LJ
    Epilepsy Behav; 2016 Jan; 54():100-3. PubMed ID: 26700063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of perampanel as a first add-on antiepileptic drug for the treatment of partial epilepsy.
    Takahashi S; Shimizu K; Inaji M; Hashimoto S; Yamamoto S; Maehara T
    Epilepsy Behav; 2019 Nov; 100(Pt A):106492. PubMed ID: 31648158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
    Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
    Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.